Karolinska Innovations AB
Records under this name other than patents Karolinska Innovations AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Karolinska Innovations AB
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,067,296 | Methods and means for modulating PGE synthase activity Term ended Term ended Aug 17, 2021 · USPTO record | Term ended | Term ended Aug 17, 2021 | USPTO record |
| US 7,192,733 | Methods and means for modulating PGE synthase activity Term ended Term ended Feb 19, 2020 · USPTO record | Term ended | Term ended Feb 19, 2020 | USPTO record |
| US 7,645,601 | Methods and means for modulating PGE synthase activity Term ended Term ended Dec 7, 2019 · USPTO record | Term ended | Term ended Dec 7, 2019 | USPTO record |
| US 6,395,502 | Method and means for modulating PGE synthase activity Term ended Term ended Nov 4, 2019 · USPTO record | Term ended | Term ended Nov 4, 2019 | USPTO record |
| US 6,235,041 | Medical device for treatment of a gap or defect in the central nerve system Formerly held Term ended Term ended Mar 1, 2019 · USPTO record | Term ended | Term ended Mar 1, 2019 | USPTO record |
| US 6,808,530 | Medical device for treatment of a gap or defect in the central nerve system Formerly held Lapsed on the fee record Ended Oct 26, 2016 · USPTO record | Lapsed on the fee record | Ended Oct 26, 2016 | USPTO record |
| US 6,780,605 | Method of diagnosing cardiovascular disease and early atherosclerosis Formerly held Lapsed on the fee record Ended Aug 24, 2016 · USPTO record | Lapsed on the fee record | Ended Aug 24, 2016 | USPTO record |
| US 6,747,136 | Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen Formerly held Term ended Term ended May 9, 2016 · USPTO record | Term ended | Term ended May 9, 2016 | USPTO record |
| US 6,538,114 | Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen Formerly held Term ended Term ended Apr 19, 2016 · USPTO record | Term ended | Term ended Apr 19, 2016 | USPTO record |
| US 6,720,310 | Transfer method for specific cellular localization of nucleic acids Formerly held Lapsed on the fee record Ended Apr 13, 2016 · USPTO record | Lapsed on the fee record | Ended Apr 13, 2016 | USPTO record |